Navigation Links
BioMS Medical announces its intention to renew a normal course issuer bid
Date:8/20/2007

Toronto Stock Exchange Symbol: MS

EDMONTON, Aug. 20 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS) a leading developer in the treatment of multiple sclerosis (MS), announced today that it is renewing its normal course issuer bid. Under the bid, which will be conducted pursuant to the rules of the Toronto Stock Exchange ("TSX"), the Company may purchase up to 1,000,000 of its Class A common shares (the "Common Shares") representing approximately 1.09% of the Company's issued and outstanding Common Shares.

The bid will commence August 24, 2007 and will expire August 23, 2008 or such earlier date as the Company may complete its purchases. The price at which the Company will purchase its shares will be the market price thereof at the time of acquisition. Purchases of Common Shares will be made in the open market through the facilities of the TSX. Any Common Shares acquired by the Company will be cancelled. The Company has 91,356,923 Common Shares issued and outstanding as of August 17, 2007. During the previous 12 months, the Company acquired 16,100 of its Common Shares at an average price of $2.68 per share by way of a normal course issuer bid. The average daily trading volume of the Common Shares on the TSX (exclusive of purchases under the Company's previous normal course issuer bid) for the period February 1, 2007 to July 31, 2007 was 62,244 shares.

The Board of Directors of the Company believes that the market price of the Common Shares may not fully reflect the value of the Company's business and its future business prospects. As a result, the Board has concluded that the purchase and cancellation of the Common Shares may represent an appropriate and desirable use of the Company's funds and provide market stability.

About BioMS Medical Corp.

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, MBP829
'/>"/>

SOURCE BioMS Medical Corp.

Copyright©2007 PR Newswire.

0

GOOD

Page: 1 2

Related biology technology :

1. Medical College receives $377K to study brain disease
2. Barriers will not stop convergence of medical technologies
3. Medical College team creates website for tracking flu
4. Biomedical engineering conference invites manufacturers
5. Visions: Wade offers straight talk on e-medical records
6. Merge unveils updated medical imaging software
7. Medical College receives $1.4M cancer grant
8. Medical technology firm lands $100K federal grant
9. Doyle outlines spending for Medical College, UWM
10. And the winners in medical design are
11. Manufacturing partnership will move into biotech and biomedical spaces

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)...ire/ -- Dr. Mate Hidvegi, inventor of Avemar ferme...se issued on November 17 by Biropharma Kft, discre...self-serving statements about its U.S. competitor ...om his office in Budapest, Hungary: ,, "The Bi...ply to AveULTRA, www.aveultra.com , is misleadi...
(Date:11/19/2009)...rstCall/ -- NeoStem, Inc. (NYSE Amex: NBS ), anno...to its shareholders, discussing the Company,s acqu...uticals Holdings, Inc. (CHBP), an integrated bio-p...ic of China. The merger gives NeoStem a controllin...td., CHBP,s primary operating subsidiary and a pro...
(Date:11/19/2009)...ss., Nov. 19 Arlington Medical Res...leading driver of antibiotic selection in nosocomi...against gram-positive and gram-negative pathogens....socomial pneumonia, surveyed European physicians r...vide appropriate coverage against common pathogens...
(Date:11/19/2009)... Aegera Therapeutics Inc. announced today the dosi...tudy of AEG35156, a targeted antisense therapeutic...dications. ,, The study, entitled "An Open-Labe...or of Apoptosis (XIAP) Antisense AEG35156 Given in...cin in AML Following Failure of a Single Standard ...
Breaking Biology Technology:American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 3Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 3Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 2
...ociation announcement validates the critical role ...ood pressure, NEW YORK, May 29 InterCure Ltd., a...-Aviv Stock Exchange (TASE: INCR), today,announced... from the,American Heart Association, American Soc...ular Nurses, Association declaring that people wit...
... FASgen Diagnostics, LLC (Baltimore),and Tetracore...ntered into,a collaboration to produce cGMP ELISA ... proprietary antibodies. The tests measure the,ove...S), which is found in,virtually all solid tumor ca...t(TM) IHC tests, currently available for research ...
...if., May 29 MAP,Pharmaceuticals, Inc. (Nasdaq: M...Rosa to the newly created position of Vice Preside...ears of human resources experience to the,Company....tec, Inc. as Vice,President of Worldwide Human Res...He was an integral part of the senior management t...
Other Biology Technology:InterCure Supports AHA Endorsement of Home Blood Pressure Monitoring 2InterCure Supports AHA Endorsement of Home Blood Pressure Monitoring 3FASgen Diagnostics, LLC Announces Production and Investment Agreement With Tetracore, Inc. 2MAP Pharmaceuticals Appoints Marco Rosa Vice President of Human Resources 2
(Date:11/20/2009)...v. 20, 2009) Scientists from the Marine Biogeoche...Naval Research Laboratory (NRL) organized and led ...an Arctic expedition to initiate methane hydrate e...patial variation of sediment contribution to Arcti...rd Cutter Polar Sea as a research platform, three ...
(Date:11/20/2009)... November 19, 2009 The estimated 4.6 million Amer...sk of developing respiratory symptoms due to poor ...nnaire study undertaken earlier this year by inves...Veterinary Medicine. , The studywhich polled mor... 50 percent of individuals working in barns compla...
(Date:11/20/2009)... of a single bacterial gene into yeast, researcher...rlands achieved three improvements in bioethanol p...ethanol, less acetate and elimination of the major...published in the scientific journal Applied and E...ethanol is made by the yeast Saccharomyces cerevis...
Breaking Biology News(10 mins):International expedition investigates climate change, alternative fuels in Arctic 2Barn personnel experience higher-than-average rates of respiratory symptoms 2Delft breakthrough in bioethanol production from agricultural waste 2Pinnacle Health Solutions Launches New Web Site Making Affordable Health Care and Benefits Easy to Understand 51415 1Pinnacle Health Solutions Launches New Web Site Making Affordable Health Care and Benefits Easy to Understand 51415 2PTSD Associated With Higher Alzheimers Dementia Risk 3B Moderate Alcohol Consumption May Lower it 4715 1PTSD Associated With Higher Alzheimers Dementia Risk 3B Moderate Alcohol Consumption May Lower it 4715 2PTSD Associated With Higher Alzheimers Dementia Risk 3B Moderate Alcohol Consumption May Lower it 4715 3PTSD Associated With Higher Alzheimers Dementia Risk 3B Moderate Alcohol Consumption May Lower it 4715 4PTSD Associated With Higher Alzheimers Dementia Risk 3B Moderate Alcohol Consumption May Lower it 4715 5PTSD Associated With Higher Alzheimers Dementia Risk 3B Moderate Alcohol Consumption May Lower it 4715 6News from Cancer 51410 1News from Cancer 51410 2News from Cancer 51410 3News from Cancer 51410 4
...e first trimester of pregnancy is clearly linked w...nes that play a role in detoxification of cigarett...n in a new study published in the journal Epidemi... birth defects. Closure of the lip occurs about 5 ...alate at week 9. If this does not happen, a cleft ...
...mi (Professor of Biopharmacy and Nanomedicine, Dep... and colleagues have received 28 million DKK (appr...cil for Strategic Research (DSF) to set The Centre...ogy (CPNN) at the Faculty of Pharmaceutical Scienc... as the Director of the Centre and Prof. Thomas Bj...
...chungsgemeinschaft (DFG, German Research Foundatio...ecially innovative and higher-risk research. They ...der the DFG,s Reinhart Koselleck Projects programm...0,000 euros and 1.25 million euros for their plann...lexibly over a five-year period. , The DFG,s Rei...
Other Biology News:First trimester smoking linked to oral clefts 2Donation for new Center for Pharmaceutical Nanotechnology and Nanotoxicology 2More freedom to take risks: DFG funds the first Reinhart Koselleck Projects 2More freedom to take risks: DFG funds the first Reinhart Koselleck Projects 3More freedom to take risks: DFG funds the first Reinhart Koselleck Projects 4
...&D Systems adds two new Stem Cell Antibody Panels ...uman Embryonic Stem Cell Marker Antibody Panel (Ca...kaline phosphatase, Nanog, Oct-3/4, SSEA-1 and SSE... Panel Plus (Catalog # SC009) contains antibodies ...
Anti-Epstein-Barr Virus (EBV) (EBNA-1) Polyclonal Antibody, Biotin Conjugated from ViroStat Inc.
Rabbit Anti-ECE-1 Polyclonal Antibody, Unconjugated from Santa Cruz Biotechnology, Inc.
Rat Anti-Mouse HAI-1 Ectodomain Monoclonal Antibody, Unconjugated, Clone 199732 from R&D Systems
Biology Products: